KLCCX
Price
$11.43
Change
+$0.15 (+1.33%)
Updated
Jul 3 closing price
Net Assets
1.25B
RGEBX
Price
$79.23
Change
+$0.77 (+0.98%)
Updated
Jul 3 closing price
Net Assets
322.86B
Interact to see
Advertisement

KLCCX vs RGEBX

Header iconKLCCX vs RGEBX Comparison
Open Charts KLCCX vs RGEBXBanner chart's image
Federated Hermes Kaufmann Large Cap C
Price$11.43
Change+$0.15 (+1.33%)
VolumeN/A
Net Assets1.25B
American Funds Growth Fund of Amer R2E
Price$79.23
Change+$0.77 (+0.98%)
VolumeN/A
Net Assets322.86B
KLCCX vs RGEBX Comparison Chart in %
Loading...
View a ticker or compare two or three
VS
KLCCX vs. RGEBX commentary
Jul 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KLCCX is a Buy and RGEBX is a Buy.

Interact to see
Advertisement
FUNDAMENTALS
Fundamentals
RGEBX has more cash in the bank: 323B vs. KLCCX (1.25B). KLCCX (0.00) and RGEBX (0.00) have matching dividends . KLCCX was incepted earlier than RGEBX: KLCCX (18 years) vs RGEBX (11 years). KLCCX (1.96) is less costly to investors than RGEBX (1.09). RGEBX is a more actively managed with annual turnover of: 25.00 vs. KLCCX (18.00). RGEBX has a lower initial minimum investment than KLCCX: RGEBX (250) vs KLCCX (1500). RGEBX annual gain was more profitable for investors over the last year : 10.04 vs. KLCCX (-28.34). RGEBX return over 5 years is better than : 45.69 vs. KLCCX (-57.71).
KLCCXRGEBXKLCCX / RGEBX
Total Expense Ratio1.891.09173%
Annual Report Gross Expense Ratio1.961.09180%
Fund Existence18 years11 years-
Gain YTD8.85710.90481%
Front LoadN/AN/A-
Min. Initial Investment1500250600%
Min. Initial Investment IRAN/AN/A-
Net Assets1.25B323B0%
Annual Yield % from dividends0.000.00-
Returns for 1 year-28.3410.04-282%
Returns for 3 years-44.2757.17-77%
Returns for 5 years-57.7145.69-126%
Returns for 10 years-37.6878.56-48%
View a ticker or compare two or three
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
PVCT0.08N/A
+5.27%
Provectus Biopharmaceuticals, Inc.
TATYY30.030.13
+0.43%
Tate & Lyle, PLC
EVAHF0.08N/A
N/A
EGF THERAMED HEALTH CORP.
SSDOF18.17N/A
N/A
Shiseido Company, Ltd.
JBPHF0.29N/A
N/A
Jacobio Pharmaceuticals Group Co Ltd.